Phase 3b, Randomized, Open-Label Study Of Bevacizumab + Temsirolimus Vs. Bevacizumab + Interferon-Alfa As First-Line Treatment In Subjects With Advanced Renal Cell Carcinoma
Phase 3b, Randomized, Open-Label Study Of Bevacizumab + Temsirolimus Vs. Bevacizumab + Interferon-Alfa As First-Line Treatment In Subjects With Advanced Renal Cell Carcinoma
Primary objective: Comparison of independently assessed progression free survival (PFS) in subjects administered Bevacizumab + Temsirolimus vs. those administered Bevacizumab + Interferon-Alfa. Secondary objectives: safety, Investigator assessed PFS, objective response rate (independently assessed), and overall survival.
Inclusion Criteria:
Exclusion Criteria:
Mont-Godinne, 5530, Belgium
Porto Alegre, Rio Grande do Sul 90430-090, Brazil
Porto Alegre, Rio Grande do Sul 90430-090, Brazil
SĂŁo Paulo, SĂŁo Paulo 01246-000, Brazil
Saint-Herblain-Nantes, 44805, France
Bhopal, Madhya Pradesh 462001, India
Kerela, Trivandrum 695011, India
Perugia, 06132, Italy
Poznan, 60-569, Poland
Warsaw, 04-141, Poland
Obninsk, Kaluga Oblast 249036, Russia
Saint-Petersburg, Leningradskaya Oblast' 188663, Russia
Moscow, 115478, Russia
Martin, 036 59, Slovakia
Taipei TOC, Taiwan 100, Taiwan
Chenivtsi, 58013, Ukraine
Kiev, 03115, Ukraine
Kiyv, 04050, Ukraine
Medychna Vul., Ivano-Frankivsk, 76018, Ukraine